From Conjecture to Clarity
Supporting the Healthcare Industry
with Local Industry Knowledge
and Marketing Expertise
e-Projection is a fully integrated consulting firm based in Tokyo, Japan.
Our experienced team serves our clients, non-Japanese biotechnology and pharmaceutical companies, with a wide spectrum of penetrating insights into the local market.
Our expertise in the pharmaceutical industry spans all areas. We are a true one-stop shop consultancy for our clients to make strategic decisions about the Japanese market.
News
Our Offerings
Demand Analysis
Our clients are industry leaders making well-informed decisions about entering markets. We help them understand the Japanese market, recognize threats and opportunities, and provide a clear idea of the value of their innovation in the Japanese market.
Tosh Nagate
DVM, PhD, MBA,
Founder & President
Tosh is the leading expert in sales forecasting and valuation in the pharmaceutical industry in Japan.Click here for details >
Pricing & Market Access Consultation
We provide a full range of pricing and market access consultations from the planning stage to post-commercialization. Our clients are able to develop fully integrated global pricing strategies that contribute to both maximizing the value of their product and succeeding commercially in the Japanese market.
Itaru Nakanishi
Advisor:
Pricing & Market Access
Itaru is a subject matter expert in pricing & market access in the Japanese pharmaceutical industry.Click here for details >
P&L Forecast/Project Valuation
Our P&L forecast/project valuation capabilities are based on our broad experience in the local pharmaceutical market and cutting-edge valuation techniques. These capabilities will provide strategic implications to maximize the corporate value of our clients.
Takashi Yamano
Advisor:
Sales & Marketing
Takashi is a subject matter expert in sales & marketing strategies in the Japanese pharmaceutical industry.Click here for details >
Clinical Development Strategy Consultation
Our deep experience in clinical trial design and our extensive network within the medical community are highly valued by clients seeking integrated global development strategies. We provide our clients with the best solutions to optimize local development plans and maximize the clinical value of the product in the Japanese market.
Shojiro Takagi
MD, PhD, MBA,
Chief Medical Officer
Dr. Takagi is a subject matter expert in planning and executing R&D and medical strategies.Click here for details >
Marketing Research
e-Projection carries out a full range of marketing research activities from KOL interviews and web-based quant surveys to secondary data collection and analysis. The local insights generated by this research help our clients understand unmet medical need in the marketplace as well as how to best adapt the profile of the local version of their product.
Tosh Nagate
DVM, PhD, MBA,
Founder & President
Tosh is the leading expert in sales forecasting and valuation in the pharmaceutical industry in Japan.Click here for details >
Regulatory Consultation
We not only identify the key regulatory requirements needed for product approval, we offer our clients value maximization plans within the regulatory window of opportunity. We present multiple scenarios in order for our clients to understand the regulatory playing field in Japan.
Click here for details >Business Development
We serve biotech, pharma, investors, and academic institutions who are interested in bringing their products and technologies to the Japanese market and/or seek business partners from the Chinese market. By applying our analytical capabilities in the BD process, we support our clients with the tools and strategies to best negotiate with their potential Japanese partners.
Click here for details >Case
Japan Opportunity Assessment
US-based biotech company developing phase II product in US/EU, trying to assess whether to expand development activities into Japan now or later. In planning for an IPO in a few months time, the company needed to ensure that investors understood the true global value of their product.
view more >Business Development Support
US biotech company developing phase III product for treatment of a cardiac disease in a hospital setting. Seeking to investigate the Japanese market for their product, find local partners with expertise in the therapeutic area.
view more >Evaluation of Clinical Value Over Competitors
Swiss-based pharmaceutical company seeking business opportunity to develop their product in Japan. Competitive products for the same disease already existed in the Japanese market. Client needed to assess the clinical value of their product and its potential to succeed in Japan, including any advantage over competitors.
view more >Validation of Clinical Development and Pricing Strategy
A German-based biotech in discussion with a Japanese company about the potential licensing of its product. The product targets the treatment of a disease with large unmet medical need currently receiving little treatment. The product was finishing its Phase III program in Europe with plans to submit the application for approval to the authorities.
view more >Pricing Strategy for Device and Drug Combination
US-based biotech exploring how to obtain premium pricing for their medical device and drug, individually as well as their combination, for a treatment of eye diseases. Client also sought to gain an understanding of the various ways for reimbursement of this combination procedure.
view more >China Affairs
We understand the China market well. This market is growing significantly as the result of changes and improvements in the regulatory environment and better organization of intellectual property law.
A Chinese company seeking new technology looked to be introduced to the growing market of products from Japan
The client needed our services to overcome challenges associated with linguistic and cultural barriers.
Blog
-
2022.05.19blog-enChuikyo approved listing of 14 Drugs on May 25
A total of 14 drugs will newly join Japan’s NHI price list on May 25. Chugai’s Vabysmo (faricimab), the first bispecific antibody in ophthalmology, for neovascular age-related macular degeneration and diabetic macular edema, is carrying the highest peak sales outlook among them, at 32 billion yen. Bayer’s non-steroidal selective mineralocorticoid receptor antagonist, Kerendia (Finelenone) also […]
-
2022.04.26blog-enLooking forward to meeting old and new contacts at Bio in San Diego
e-Projection will be participating in Bio International Convention ! Meet with us at BIO 2022 in San Diego, June 13-16 ! This is the most important event to promote us as an ideal partner for all seeking opportunity in Japan. And face-to face partnering opportunities are essential to progress in biotech, encouraging us to expand […]
-
2022.04.14blog-enChuikyo approved listing of 8 Drugs on April 20
8 new drugs will join the reimbursement price list in Japan on April 20. In the FY2022 Drug pricing reform, the Chuikyo introduced “the premium coefficient 0 (less than 50% degree of disclosure)”, which is a new rule to improve transparency of manufacturing costs used in the cost calculation method for newly priced products, particularly […]
-
2022.03.18blog-enJoin us at BIO-EUROPE SPRING DIGITAL 2022!
We are excited to join BIO-Europe Spring. We had a tremendous turnout during the last year’s BIO-Europe Spring. This year, Bio Europe has become digital as it did last year, but this is still a great event! Meet us on March 28 to 31, our team will be very pleased to discuss with you all! […]
-
2022.02.04blog-enNew Light on Fertility Treatments;
9 Drugs for Fertility Treatment to Be Listed in AprilIn line with the introducing health coverage for fertility treatments from next April, the Central Social Insurance Medical Council (Chuikyo) approved the NHI price list of nine drugs for fertility treatments. Listing is scheduled for April 1. Health coverage for infertility treatment is one of the measures compiled by former Prime Minister Yoshihide Suga to improve Japan’s low […]
We help non-Japanese pharma/biotech companies understand and expand into the Japanese market.
